If the non-radiolabeled TM601 receives FDA approval for malignant glioma, it will entitle TransMolecular to exclusive marketing rights for the compound for the treatment of malignant glioma for seven years following the NDA approval.
TM601 is a synthetic version of chlorotoxin, a naturally occurring peptide derived from scorpion venom, which is highly specific in targeting both primary tumors and metastases.
Michael Egan, president and CEO of TransMolecular, said: “This designation is part of TransMolecular’s strategy to advance this program so that patients with this poor-prognosis disease may eventually have a new treatment option available to them.”